GlassScriptPhysician profile
Samuel Kim
NPI 1174257703
$901.21
in general payments reported to CMS, 2019-2025
10 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $134 · 2023: $138 · 2024: $499 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $176.34 | 2023-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $124.00 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $119.95 | 2024 | Xdemvy |
| Bausch & Lomb Americas INC. | $114.38 | 2022-2025 | Infuse, Biotrue |
| Coopervision INC. | $96.77 | 2024-2025 | Myday Contact Lens |
| Horizon Therapeutics Plc | $75.00 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $69.77 | 2023-2025 | |
| Alcon Vision LLC | $60.89 | 2022-2023 | Total30 |
| Abbvie INC. | $49.95 | 2022-2023 | |
| Biotissue Holdings INC. | $14.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.